APTITUDE HEALTH®

EPICS

Global Perspectives in Gastrointestinal Malignancies in 2024

July 8 and 12, 2024

Full report

Report Contents

EPICS

Meeting Snapshot

EPICS

EPICS

VIRTUAL CLOSED-DOOR ROUNDTABLE

DATE:
July 8 and 12, 2024

DISEASE STATE AND DATA PRESENTATIONS by key experts

INSIGHTS REPORT including postmeeting analyses and actionable recommendations

PANEL: Key experts in GI cancer

- 5 from US
- 3 from Europe

GI CANCER-SPECIFIC DISCUSSIONS on latest research updates, therapeutic advances, and their application in clinical decision-making

Panel Consisting of 8 Global GI Cancer Experts

EPICS



Dirk Arnold, MD, PhD
University of Hamburg

Nataliya Uboha, MD, PhD
University of Wisconsin Madison

CHAIR:
Howard S. Hochster, MD
Rutgers Cancer Institute of New Jersey

Julien Taieb, MD, PhD
Université de Paris

Gerald Prager, MD
Medical University of Vienna

Kristen Ciombor, MD
Vanderbilt University Medical Center

Efrat Dotan, MD
Fox Chase Cancer Center

Tanios Bekaii-Saab, MD, FACP
Mayo Clinic Cancer Center

APTITUDE HEALTH®

Meeting Agenda: Day 1

EPICS

Time (ET/CEST)	Topic	Speaker/Moderator
9.30 AM – 9.35 AM/15.30 – 15.35	Welcome and Introductions	Howard Hochster, MD
9.35 AM – 9.45 AM/15.35 – 15.45	**Metastatic Colorectal Cancer – Chemotherapy, Targeted Therapies, and Biomarker-Driven Treatments**	Dirk Arnold, MD, PhD
9.45 AM – 10.15 AM/15.45 – 16.15	Discussion	All
10.15 AM – 10.20 AM/16.15 – 16.20	Key Takeaways	Dirk Arnold, MD, PhD
10.20 AM – 10.30 AM/16.20 – 16.30	**Colorectal Cancer – Immunotherapy**	Julien Taieb, MD, PhD
10.30 AM – 11.00 AM/16.30 – 17.00	Discussion	All
11.00 AM – 11.05 AM/17.00 – 17.05	Key Takeaways	Julien Taieb, MD, PhD
11.05 AM – 11.25 AM/17.05 – 17.25	**ctDNA Updates and Integration in Clinical Practice**	Howard Hochster, MD
11.25 AM – 11.35 AM/17.25 – 17.35	BREAK	All
11.35 AM – 11.50 AM/17.35 – 17.50	**Rectal Cancer**	Kristen Ciombor, MD
11.50 AM – 12.20 PM/17.50 – 18.20	Discussion	All
12.20 PM – 12.25 PM/18.20 – 18.25	Key Takeaways	Kristen Ciombor, MD
12.25 PM – 12.30 PM/18.25 – 18.30	Summary and Closing Remarks	Howard Hochster, MD

Meeting Agenda: Day 2

EPICS

Time (ET/CEST)	Topic	Speaker/Moderator
9.30 AM – 9.35 AM/15.30 – 15.35	Welcome and Introductions	Howard Hochster, MD
9.35 AM – 9.45 AM/15.35 – 15.45	**Gastroesophageal Junction (GEJ) and Gastric Cancer**	Nataliya Uboha, MD, PhD
9.45 AM – 10.10 AM/15.45 – 16.10	Discussion	All
10.10 AM – 10.15 AM/16.10 – 16.15	Key Takeaways	Nataliya Uboha, MD, PhD
10.15 AM – 10.25 AM/16.15 – 16.25	**Hepatocellular Carcinoma (HCC)**	Tanios Bekaii-Saab, MD, FACP
10.25 AM – 10.45 AM/16.25 – 16.45	Discussion	All
10.45 AM – 10.50 AM/16.45 – 16.50	Key Takeaways	Tanios Bekaii-Saab, MD, FACP
10.50 AM – 11.00 AM/16.50 – 17.00	BREAK	All
11.00 AM – 11.10 AM/17.00 – 17.10	**Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)**	Howard Hochster, MD
11.10 AM – 11.20 AM/17.10 – 17.20	**Pancreatic Cancer**	Efrat Dotan, MD
11.20 AM – 11.40 AM/17.20 – 17.40	Discussion	All
11.40 AM – 11.45 AM/17.40 – 17.45	Key Takeaways	Efrat Dotan, MD
11.45 AM – 11.55 AM/17.45 – 17.55	**Biliary Tract Cancer**	Gerald Prager, MD
11.55 AM – 12.20 PM/17.55 – 18.20	Discussion	All
12.20 PM – 12.25 PM/18.20 – 18.25	Key Takeaways	Gerald Prager, MD
12.25 PM – 12.30 PM/18.25 – 18.30	Summary and Closing Remarks	Howard Hochster, MD

APTITUDE HEALTH®

EPICS

Metastatic Colorectal Cancer – Chemotherapy, Targeted Therapies, and Biomarker-Driven Treatments

Metastatic Colorectal Cancer – Chemotherapy, Targeted Therapies, and Biomarker-Driven Treatments (1/3)

Presented by Dirk Arnold, MD, PhD

EPICS

Highlights From Recent Congresses

Hyperselection and anti-EGFR therapy

Metastatic Colorectal Cancer – Chemotherapy, Targeted Therapies, and Biomarker-Driven Treatments (2/3)

Presented by Dirk Arnold, MD, PhD

EPICS

Highlights From Recent Congresses

Anti-EGFR + *KRAS* G12C inhibitors

CodeBreaK 300

Metastatic Colorectal Cancer – Chemotherapy, Targeted Therapies, and Biomarker-Driven Treatments (3/3)

Presented by Dirk Arnold, MD, PhD

EPICS

Highlights From Recent Congresses

New targets

APTITUDE HEALTH®

EPICS

Key Insights

Metastatic Colorectal Cancer – Chemotherapy, Targeted Therapies, and Biomarker-Driven Treatments

Metastatic Colorectal Cancer – Chemotherapy, Targeted Therapies, and Biomarker-Driven Treatments (1/3)

EPICS

APTITUDE HEALTH®

Metastatic Colorectal Cancer – Chemotherapy, Targeted Therapies, and Biomarker-Driven Treatments (2/3)

EPICS

ongoing trials will help clarify the optimal sequencing of agents

- Experts are still using a [redacted] regimen (± bevacizumab and panitumumab) first-line, followed by T-DM1 second-line, for most patients
- Most experts are using trastuzumab deruxtecan third-line, but will prioritize the tucatinib triplet for patients with evidence of brain metastases
- The tucatinib triplet may also be used in the second-line setting, before T-DM1, for patients with documented brain metastases
  - If tucatinib is used second-line, experts are divided on whether they would currently use T-DM1 or trastuzumab deruxtecan third-line
    - Results of the ongoing DESTINY-Breast03 trial comparing trastuzumab deruxtecan vs T-DM1 will help to clarify the optimal sequence of these ADCs
- Trastuzumab deruxtecan and the tucatinib triplet may also be used earlier than third-line in patients who recur following treatment with trastuzumab, pertuzumab, and T-DM1 in the (neo)adjuvant setting, but this represents a small fraction of patients
- Patient preferences can also factor into the sequencing of these new agents (eg, 3 drugs vs 1 drug, concern about hair loss vs diarrhea)
- The impressive efficacy of trastuzumab deruxtecan and the tucatinib regimen have pushed other options, such as trastuzumab chemotherapy combinations, neratinib, and margetuximab, to later lines of therapy

Dr Pegram

We used to run out of good options and we would just default to the mean of chemotherapy plus trastuzumab in the salvage setting, but now we have so many great choices that that really takes a backseat. It's really been exciting to have multiple options for patients after T-DM1 — again, practice changing, unprecedented

APTITUDE HEALTH®

Metastatic Colorectal Cancer – Chemotherapy, Targeted Therapies, and Biomarker-Driven Treatments (3/3)

EPICS

ongoing trials will help clarify the optimal sequencing of agents

- Experts are still using a [redacted] regimen (± bevacizumab and panitumumab) first-line, followed by [redacted] second-line, for most patients
- Most experts are using trastuzumab deruxtecan third-line, but will prioritize the tucatinib triplet for patients with evidence of brain metastases
- The tucatinib triplet may also be used in the second-line setting, before [redacted], for patients with documented brain metastases
  - If tucatinib is used second-line, experts are divided on whether they would currently use [redacted] or trastuzumab deruxtecan third-line
    - Results of the ongoing DESTINY-Breast03 trial comparing trastuzumab deruxtecan vs [redacted] will help to clarify the optimal sequence of these ADCs
- Trastuzumab deruxtecan and the tucatinib triplet may also be used earlier than third-line in patients who recur following treatment with trastuzumab, pertuzumab, and [redacted] in the (neo)adjuvant setting, but this represents a small fraction of patients
- Patient preferences can also factor into the sequencing of these new agents (eg, 3 drugs vs 1 drug, concern about hair loss vs diarrhea)
- The impressive efficacy of trastuzumab deruxtecan and the tucatinib regimen have pushed other options, such as trastuzumab chemotherapy combinations, neratinib, and margetuximab, to later lines of therapy

Dr Pegram

We used to run out of good options and we would just default to the mean of chemotherapy plus trastuzumab in the salvage setting, but now we have so many great choices that that really takes a backseat. It's really been exciting to have multiple options for patients after [redacted] — again, practice changing, unprecedented

APTITUDE HEALTH®

APTITUDE HEALTH®

EPICS

Colorectal Cancer – Immunotherapy

Colorectal Cancer – Immunotherapy (1/3)

Presented by Julien Taieb, MD, PhD

EPICS

Highlights From Recent Congresses

MSI-H mCRC

CheckMate 8HW – PFS2

Colorectal Cancer – Immunotherapy (2/3)

Presented by Julien Taieb, MD, PhD

EPICS

Highlights From Recent Congresses

MSI-H early-stage CRC (cont.)

EECD 1703 POCHI

Colorectal Cancer – Immunotherapy (3/3)

Presented by Julien Taieb, MD, PhD

EPICS

Highlights From Recent Congresses

New targets

ARC9

APTITUDE HEALTH®

EPICS

Key Insights

Colorectal Cancer – Immunotherapy

Colorectal Cancer – Immunotherapy (1/3)

EPICS

APTITUDE HEALTH®

Colorectal Cancer – Immunotherapy (2/3)

EPICS

APTITUDE HEALTH®

Colorectal Cancer – Immunotherapy (3/3)

EPICS

Immunotherapy in early-stage disease

APTITUDE HEALTH®

EPICS

ctDNA Updates and Integration in Clinical Practice

ctDNA Updates and Integration in Clinical Practice (1/3)

Presented by Howard Hochster, MD

EPICS

Highlights From Recent Congresses

ctDNA and MRD in the adjuvant setting

CIRCULATE-Japan

ctDNA Updates and Integration in Clinical Practice (2/3)

Presented by Howard Hochster, MD

EPICS

Highlights From Recent Congresses

ASCO and ESMO GI 2024

ctDNA Updates and Integration in Clinical Practice (3/3)

Presented by Howard Hochster, MD

EPICS

APTITUDE HEALTH®

APTITUDE HEALTH®

EPICS

Key Insights

ctDNA Updates and Integration in Clinical Practice

ctDNA Updates and Integration in Clinical Practice (1/2)

EPICS

ctDNA Updates and Integration in Clinical Practice (2/2)

EPICS

ctDNA assessment in clinical trials and clinical practice (cont.)

APTITUDE HEALTH®

EPICS

Rectal Cancer

Rectal Cancer (1/3)

Presented by Kristen Ciombor, MD

EPICS

Highlights From Recent Congresses

Immunotherapy in locally advanced rectal cancer (LARC)

Rectal Cancer (2/3)

Presented by Kristen Ciombor, MD

EPICS

Highlights From Recent Congresses

Nivolumab + regorafenib (MSI-H or MSS)

Nivolumab + regorafenib + SCRT – REGINA

Rectal Cancer (3/3)

Presented by Kristen Ciombor, MD

EPICS

Highlights From Recent Congresses

Total neoadjuvant treatment (TNT)

APTITUDE HEALTH®

EPICS

Key Insights

Rectal Cancer

Rectal Cancer (1/3)

EPICS

Total neoadjuvant therapy (TNT) in MSS rectal cancer

Rectal Cancer (2/3)

EPICS

Total neoadjuvant therapy (TNT) in MSS rectal cancer

Rectal Cancer (3/3)

EPICS

Dr Pegram
We used to run out of good options and we would just regress to the mean of chemotherapy plus trastuzumab in the salvage setting, but now we have so many great choices that that really takes a backseat. It's really been exciting to have multiple options for patients after T-DM1 — again, practice changing, unprecedented.

APTITUDE HEALTH®

APTITUDE HEALTH®

EPICS

Gastroesophageal Junction and Gastric Cancer

GEJ and Gastric Cancer (1/3)

Presented by Nataliya Uboha, MD, PhD

EPICS

Highlights From Recent Congresses

Early setting of esophageal and GEJ cancers

ESOPEC trial: FLOT vs chemoradiation

GEJ and Gastric Cancer (2/3)

Presented by Nataliya Uboha, MD, PhD

EPICS

Highlights From Recent Congresses

Biomarkers in advanced gastric and GEJ cancers

GEJ and Gastric Cancer (3/3)

Presented by Nataliya Uboha, MD, PhD

EPICS

Highlights From Recent Congresses

Emerging agents in gastric and GEJ cancers

APTITUDE HEALTH®

EPICS

Key Insights

GEJ and Gastric Cancer

GEJ and Gastric Cancer – Early Setting (1/2)

EPICS

GEJ and Gastric Cancer – Early Setting (2/2)

EPICS

Early setting of esophageal and GEJ cancers (cont.)

GEJ and Gastric Cancer – Molecular Testing

EPICS

ongoing trials will help clarify the optimal sequencing of agents

- Experts are still using a CLEOPATRA-like regimen (a taxane plus trastuzumab and pertuzumab) first-line, followed by T-DM1 second-line, for most patients
- Most experts are using trastuzumab deruxtecan third-line, but will prioritize the tucatinib triplet for patients with evidence of brain metastases
- The tucatinib triplet may also be used in the second-line setting, before T-DM1, for patients with documented brain metastases
  - If tucatinib is used second-line, experts are divided on whether they would currently use T-DM1 or trastuzumab deruxtecan third-line
    - Results of the ongoing DESTINY-Breast03 trial comparing trastuzumab deruxtecan vs T-DM1 will help to clarify the optimal sequence of these ADCs
- Trastuzumab deruxtecan and the tucatinib triplet may also be used earlier than third-line in patients who recur following treatment with trastuzumab, pertuzumab, and T-DM1 in the (neo)adjuvant setting, but this represents a small fraction of patients
- Patient preferences can also factor into the sequencing of these new agents (eg, 3 drugs vs 1 drug, concern about hair loss vs diarrhea)
- The impressive efficacy of trastuzumab deruxtecan and the tucatinib regimen have pushed other options, such as trastuzumab-chemotherapy combinations, nivolumab, and margetuximab, to later lines of therapy

Dr Pegram

We used to run out of good options and we would just regress to the mean of chemotherapy plus trastuzumab in the salvage setting, but now we have so many great choices that that really takes a backseat. It's really been exciting to have multiple options for patients after T-DM1 — again, practice changing, unprecedented

GEJ and Gastric Cancer – Advanced Setting (1/2)

EPICS

Immunotherapies and surgery in advanced gastric and GEJ cancers

GEJ and Gastric Cancer – Advanced Setting (2/2)

EPICS

Dr Pegram

We used to run out of good options and we would just regress to the mean of chemotherapy plus trastuzumab in the salvage setting, but now we have so many great choices that that really takes a backseat. It's really been exciting to have multiple options for patients after T-DM1 — again, practice changing, unprecedented.

APTITUDE HEALTH®

APTITUDE HEALTH®

EPICS

Hepatocellular Carcinoma

HCC

Presented by Tanios Bekaii-Saab, MD, FACP

EPICS

Highlights From Recent Congresses

Immunotherapies in frontline HCC treatment

CheckMate 9DW trial: Ipilimumab-nivolumab vs lenvatinib

APTITUDE HEALTH®

EPICS

Key Insights

HCC

HCC – Early Setting (1/2)

EPICS

Dr Pugnale

We used to run out of good options and we would just regress to the mean of chemotherapy plus trastuzumab in the salvage setting, but now we have so many great choices that that really takes a backseat. It's really been exciting to have multiple options for patients after T-DXd — again, practice changing, unprecedented.

APTITUDE HEALTH®

HCC – Early Setting (2/2)

EPICS

Dr Pugnaire

We used to run out of good options and we would just regress to the mean of chemotherapy plus trastuzumab in the salvage setting, but now we have so many great choices that that really takes a backseat. It's really been exciting to have multiple options for patients after T-DXd — again, practice changing, unprecedented.

APTITUDE HEALTH®

HCC – Advanced Setting (1/3)

EPICS

APTITUDE HEALTH®

HCC – Advanced Setting (2/3)

EPICS

APTITUDE HEALTH®

HCC – Advanced Setting (3/3)

EPICS

APTITUDE HEALTH®

APTITUDE HEALTH®

EPICS

Gastroenteropancreatic Neuroendocrine Tumors

GEP-NETs

Presented by Howard Hochster, MD

EPICS

Highlights From Recent Congresses

PRRT and the NETTER-2 trial

^{177}Lu-DOTATATE showed significant improvement in

APTITUDE HEALTH®

EPICS

Key Insights

GEP-NETs

GEP-NETs (1/2)

EPICS

Dr Pograns

We used to run out of good options and we would just regress to the mean of chemotherapy plus trastuzumab in the salvage setting, but now we have so many great choices that that really takes a backseat. It's really been exciting to have multiple options for patients after T-DM1 — again, practice changing, unprecedented.

GEP-NETs (2/2)

EPICS

APTITUDE HEALTH®

EPICS

Pancreatic Cancer

Pancreatic Cancer – Early Setting

Presented by Efrat Dotan, MD

EPICS

Highlights From Recent Congresses

The role of radiation in early disease: NRG/RTOG 0848 trial

NRD/RTOG 0848 trial

Pancreatic Cancer – Metastatic Setting (1/2)

Presented by Efrat Dotan, MD

EPICS

Highlights From Recent Congresses

The PASS-01 trial

PASS-01 trial

Pancreatic Cancer – Metastatic Setting (2/2)

Presented by Efrat Dotan, MD

EPICS

Highlights From Recent Congresses

OPTIMIZE-1

OPTIMIZE-1 trial

APTITUDE HEALTH®

EPICS

Key Insights

Pancreatic Cancer

Pancreatic Cancer (1/3)

EPICS



Pancreatic Cancer (2/3)

EPICS

Pancreatic Cancer (3/3)

EPICS

Dr Pegram

We used to run out of good options and we would just regress to the mean of chemotherapy plus trastuzumab in the salvage setting, but now we have so many great choices that that really takes a backseat. It's really been exciting to have multiple options for patients after T-DXd — again, practice changing, unprecedented.

APTITUDE HEALTH®

EPICS

Biliary Tract Cancer

Biliary Tract Cancer (1/3)

Presented by Gerald Prager, MD

EPICS

Highlights From Recent Congresses

Current practices

TOPAZ-1 trial

Biliary Tract Cancer (2/3)

Presented by Gerald Prager, MD

EPICS

Highlights From Recent Congresses

Improving responses with targeted agents

HERIZON-BTC-01 2 trial

Biliary Tract Cancer (3/3)

Presented by Gerald Prager, MD

EPICS

Highlights From Recent Congresses

Improving responses with targeted agents

Phase II study of sitravatinib in combination with tislelizumab

APTITUDE HEALTH®

EPICS

Key Insights

Biliary Tract Cancer

Biliary Tract Cancer (1/3)

EPICS

Dr Pugnaire

We used to run out of good options and we would just regress to the mean of chemotherapy plus trastuzumab in the salvage setting, but now we have so many great choices that that really takes a backseat. It's really been exciting to have multiple options for patients after T-DXd — again, practice changing, unprecedented.

Biliary Tract Cancer (2/3)

EPICS

APTITUDE HEALTH®

Biliary Tract Cancer (3/3)

EPICS

APTITUDE HEALTH®

APTITUDE HEALTH®

US 5901-B Peachtree Dunwoody Road
Suite 415, Atlanta, GA 30328, US

EU Laan van Nieuw Oost-Indië 133 F
2593 BM The Hague, the Netherlands

UK 6th Floor, 2 Kingdom Street
London, W2 6BD, United Kingdom

aptitudehealth.com